Is the result of breast Tc-99m mibi scintigraphy a prognostic factor for survival in invasive breast cancer?

e22175 Background: The present study analyzed the impact of p53 expression and TP53 codon 72 polymorphism on the prognosis in patients with operated invasive breast cancer. Methods: Two hundred thirty-four patients with ductal breast cancer who underwent surgery with curative intent were enrolled in the present study. The tumor expressions of p53, ER, PR, and HER2 were graded immunohistochemically and TP53 codon 72 polymorphism was determined by a PCR-RFLP assay using genomic DNA extracted from paraffin-embedded tissue. Results: The median age was 49 (range, 24–82) years, and 134 (57.3%) patients were premenopause at the time of diagnosis. Pathologic stages after surgery were as follows: stage I (n=77, 32.9%), stage II (n=110, 47.0%), and stage III (n=47, 20.1%). Tumor overexpression of p53 protein was observed in 59 (25.2%) patients and was associated with an unfavorable relapse-free survival (RFS) in an univariate analysis adjusted to age, stage, and menstrual status. In a multivariate analysis, p53 overexpression was an independent prognostic factor for RFS (HR=2.36; 95% CI=1.09–5.13; p=0.030). However, no associations were observed between the genotype of TP53 codon 72 polymorphism and survival or clinicopathologic characteristics. Conclusions: Overexpression of p53 protein can be considered as a prognostic factor for RFS in the breast cancer patients after surgery. No significant financial relationships to disclose.

Download Full-text

The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph Node-Positive Operable Invasive Breast Cancer

Journal of Breast Cancer ◽

10.4048/jbc.2011.14.3.198 ◽

2011 ◽

Vol 14 (3) ◽

pp. 198 ◽

Cited By ~ 42

Author(s):

Young Ju Song ◽

Sun Hyoung Shin ◽

Jin Seong Cho ◽

Min Ho Park ◽

Jung Han Yoon ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Prognostic Factor ◽

Invasive Breast Cancer ◽

Lymphovascular Invasion ◽

Node Positive ◽

Lymph Node Positive

Download Full-text

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05955-1 ◽

2020 ◽

Author(s):

Yousif A. Kariri ◽

Mansour Alsaleem ◽

Chitra Joseph ◽

Sami Alsaeed ◽

Abrar Aljohani ◽

...

Keyword(s):

Breast Cancer ◽

Patient Outcome ◽

Prognostic Factor ◽

Invasive Breast Cancer ◽

Immune Cell ◽

Therapeutic Potential ◽

Early Stage ◽

Prognostic Significance ◽

Isg15 Expression ◽

Interferon Stimulated Gene 15

Abstract Background Lymphovascular invasion (LVI) is a prognostic factor in early-stage invasive breast cancer (BC). Through bioinformatics, data analyses of multiple BC cohorts revealed the positive association between interferon-stimulated gene 15 (ISG15) LVI status. Thus, we explored the prognostic significance of ISG15 in BC. Methods The prognostic significance of ISG15 mRNA was assessed in METABRIC (n = 1980), TCGA (n = 854) and Kaplan–Meier Plotter (n = 3951). ISG15 protein was evaluated using immunohistochemistry (n = 859) in early-stage invasive BC patients with long-term follow-up. The associations between ISG15 expression and clinicopathological features, expression of immune cell markers and patient outcome data were evaluated. Results High mRNA and protein ISG15 expression were associated with LVI, higher histological grade, larger tumour size, hormonal receptor negativity, HER2 positivity, p53 and Ki67. High ISG15 protein expression was associated with HER2-enriched BC subtypes and immune markers (CD8, FOXP3 and CD68). High ISG15 mRNA and ISG15 expressions were associated with poor patient outcome. Cox proportional multivariate analysis revealed that the elevated ISG15 expression was an independent prognostic factor of shorter BC-specific survival. Conclusion This study provides evidence for the role of ISG15 in LVI development and BC prognosis. Further functional studies in BC are warranted to evaluate the therapeutic potential of ISG15.

Download Full-text

Expression of E26 transformation specific-1 (ETS-1) in tumour-infiltrating lymphocytes (TILs) is adverse prognostic factor in invasive breast cancer

Breast Disease ◽

10.3233/bd-200449 ◽

2021 ◽

pp. 1-7

Author(s):

Velibor Puzovic ◽

Jasminka Jakic-Razumovic

Keyword(s):

Breast Cancer ◽

Prognostic Factor ◽

Invasive Breast Cancer ◽

Histological Grade ◽

Tumour Size ◽

Disease Free Survival ◽

Proliferation Index ◽

Adverse Prognostic Factor ◽

Tumour Infiltrating Lymphocytes ◽

Infiltrating Lymphocytes

AIM OF THE STUDY: The microenvironment depicts the relationship between tumour cells and immune response, and every insight into stromal lymphocytes could contribute to explain their role and activity. E26 transformation specific-1 (ETS-1) is a transcription factor that is active in cell proliferation. We analysed its immunohistochemical expression in tumour infiltrating lymphocytes (TILs) in invasive breast cancer and correlated its immunohistochemical score (IHS) to traditional predictive and prognostic factors and survival. MATERIALS AND METHODS: The sample contains data of 121 patients with invasive breast cancer, not otherwise specified (NOS) who underwent mammectomy and lymphadenectomy in 2002 at the Clinical Hospital Centre Zagreb, Croatia. Paraffin blocks of the tumour tissue were collected from the pathological archive. Three representative areas of every patient were chosen and multiple tissue samples were made. Immunohistochemical staining with rabbit anti-ETS-1 (Novocastra, UK) and the ABC method was performed on a DAKO Autostainer. The expression of ETS-1 in stromal TILs was analysed on an Olympus 41 microscope. The IHS score was calculated and correlated with clinical and pathological parameters, as well as disease-free survival (DFS) and overall survival (OS). RESULTS: In almost all patients (95%), some expression of ETS-1 in TILs was found. A moderate/high score of ETS-1 correlated with larger tumour size and higher histological grade, high proliferation index and low progesterone receptors (PgR). The patients with moderate/high ETS-1 expression in TILs had shorter DFS than patients with weak/negative ETS-1 expression. CONCLUSION: In invasive breast cancer NOS, expression of ETS-1 in TILs is an adverse prognostic factor.

Download Full-text